100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Reaches Agreements to Resolve a Portion of Litigation Involving Specialty Formulas for Preterm Infants
Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
Kevin Conroy Appointed to Abbott Laboratories Board of Directors
Notice of Proposed Settlement of Consolidated Derivative Action, Final Settlement Hearing, and Right to Appear
First-Quarter 2026 Results; Updates Guidance To Reflect Acquisition Of Exact Sciences
Other Events, Press Release
Annual Report to Security Holders
Abbott Laboratories Issues $20 Billion in Senior Notes
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
S-3ASR
Definitive Proxy Statement
Additional Proxy Materials
Additional Proxy Soliciting Materials
Statement of Changes in Beneficial Ownership
Specialized Disclosure Report
Free Writing Prospectus
Submission Upload
Correspondence